Hepatocellular carcinoma: Clinical study of long-term survival and choice of treatment modalities

doi:10.3748/wjg.v19.i23.3649

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 23

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5817)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

440

HTML

3447

Figures (1-1)

163

Tables (1-5)

171

Sum=4221

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

958

Download

638

Sum=1596

Jun 21, 2013 (publication date) through May 10, 2024

Times Cited of This Article

Times Cited (26)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Jun 21, 2013; 19(23): 3649-3657
Published online Jun 21, 2013. doi: 10.3748/wjg.v19.i23.3649

Table 2 Comparison of treatment modalities between 5-year survival group and 10-year survival group for hepatocellular carcinoma

Treatment modalities by tumor type	5-yr survival group	10-yr survival group	P value between groups	P value between overall groups
No. of treatment modalities				0.092
Surgery alone	609	235
TACE alone	214	80
Surgery + TACE	458	125
TACE + RFA	85	28
Surgery + TACE + RFA	150	52
Tumor size ≤ 5 cm (maximum diameter)				0.097
Surgery alone	244 (3.53 ± 1.03)	100 (3.48 ± 1.06)	0.217
TACE alone	92 (2.59 ± 1.16)	38 (3.58 ± 1.16)	0.087
Surgery + TACE	133 (3.90 ± 1.02)	43 (3.47 ± 1.03)	0.192
TACE + RFA	72 (3.10 ± 1.16)	21 (2.93 ± 1.10)	0.824
Surgery + TACE + RFA	82 (3.88 ± 0.91)	26 (3.42 ± 0.98)	0.314
Tumor size > 5 cm (maximum diameter)				0.106
Surgery alone	365 (8.16 ± 2.27)	135 (8.532 ± 2.71)	0.130
TACE alone	122 (9.31 ± 2.94)	42 (9.36 ± 2.26)	0.925
Surgery + TACE	325 (9.59 ± 3.16)	82 (9.09 ± 2.50)	0.624
TACE + RFA	13 (11.68 ± 3.74)	7 (10.47 ± 5.59)	0.548
Surgery + TACE + RFA	68 (7.19 ± 3.02)	26 (10.65 ± 4.63)	0.131
Uninodular HCC				0.039
Surgery alone	531	223
TACE alone	178	75
Surgery + TACE	382	113
TACE + RFA	57	24
Surgery + TACE + RFA	100	50
Multinodular HCC
Surgery alone	78	12
TACE alone	36	5
Surgery + TACE	76	12
TACE + RFA	28	4		0.445
Surgery + TACE + RFA	50	2
AFP > 400 ng/mL (AFP value)				0.289
Surgery alone	280 (16053.09 ± 27804.11)	102 (18092.07 ± 26818.62)	0.450
TACE alone	66 (15876.11 ± 30406.63)	28 (10984.83 ± 18402.28)	0.270
Surgery + TACE	188 (21164.79 ± 31964.15)	47 (25114.26 ± 31807.02)	0.385
TACE + RFA	32 (742.50 ± 0.00)	12 (22597.20 ± 28745.64)	0.667
Surgery + TACE + RFA	56 (1884.33 ± 953.25)	19 (8789.88 ± 21862.41)	0.091
AFP < 400 ng/mL (AFP value)				0.065
Surgery alone	329 (45.50 ± 71.08)	133 (56.35 ± 91.86)	0.853
TACE alone	148 (38.60 ± 71.56)	52 (38.09 ± 48.30)	0.355
Surgery + TACE	270 (66.35 ± 98.86)	78 (43.02 ± 74.45)	0.738
TACE + RFA	69 (133.34 ± 145.64)	16 (44.81 ± 43.02)	0.579
Surgery + TACE + RFA	94 (96.06 ± 138.35)	33 (15.43 ± 8.21)	0.064

AFP: α-fetoprotein; TACE: Transcatheter arterial chemoembolization; RFA: Radiofrequency ablation; HCC: Hepatocellular carcinoma.

Citation: Wu KT, Wang CC, Lu LG, Zhang WD, Zhang FJ, Shi F, Li CX. Hepatocellular carcinoma: Clinical study of long-term survival and choice of treatment modalities. World J Gastroenterol 2013; 19(23): 3649-3657
URL: https://www.wjgnet.com/1007-9327/full/v19/i23/3649.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i23.3649